TAKE Solutions Ltd, leaders in Supply Chain Management (SCM) and Life Sciences products, has signed a deal with the Chennai-based pharmaceutical company, Novel Therapeutics Pvt. Ltd.
Novel Therapeutics is engaged in the development, manufacturing and marketing of generic pharmaceutical formulations, specifically dedicated for US and other regulated markets.
According to sources, this will be TAKE Solutions' first deal in Chennai for the deployment of the increasingly popular PharmaReady eCTD and SPL solution suite. This comes on the back of successful deals signed for PharmaReady installations and will be TAKE's ninth client win in the country in the past nine months.
Talking about the deal, Ramesh L, vice president - Sales, Life Sciences APAC, TAKE Solutions said, "We are thrilled with this partnership with a highly respectable global player in the drug products market. This also reiterates the fact that the Indian pharma industry has matured enough to realize the benefits of investing in cutting-edge technology solutions for long-term business gains. Being associated with Novel's aim of providing their customers with niche technology-based drug products also encourages us to think that we are on the right path."
J Jayaseelan, director Novel Therapeutics Pvt Ltd said, "The Pharma Ready eCTD and the SPL solution suite is just the kind of cutting edge technology we were looking for to help us reach our goal of providing new and generic technology-based drug products to the global market. We as a company believe in our ability to use efficient processes and latest technologies for best results and TAKE Solutions seems to be a more than able partner in this journey."
TAKE Solutions is a leading international business technology company with products backed by a strong domain expertise in Life Sciences and Supply Chain Management - to provide cost-effective, comprehensive solutions for businesses.
Headquartered in Chennai, TAKE primarily drives its SCM Domain Excellence Centre and Global Delivery Centre from India. Company has strong presence in the USA with Life Sciences Domain Excellence centers located in Princeton, New Jersey.
Novel Therapeutics Private Limited (NTPL) founded in November, 2007 by industry veteran J Jayaseelan as director. Novel is a cent per cent Export Oriented Unit (EOU) engaged in 'Development, Manufacturing and Marketing' of Generic pharmaceutical formulations specifically dedicated for United States of America (USA) and other regulated markets. NTPL has a technical tie-up for its R&D activities from well renowned scientists based in USA ably supported by a dozen Senior Scientists working at its Chennai site. NTPL offers the unmatching dual benefits of US technology at Indian Cost.
The NTPL has got state-of-the-art Research & Development (R&D) and Manufacturing facility at Kelambakkam near Chennai, Tamil Nadu, India. The facility has a total built up area of 65000 sq ft spread over a plot of 3 acres comprising the R&D, Manufacturing.
The R&D and Manufacturing facility is matching with the International Standards. NTPL is working on robust pipeline of its own ANDAs and has a target to achieve valuation of INR 500 Cr in the next five years.